<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Koning, B.A.E. de</title>
    <link>http://repub.eur.nl/res/aut/14002/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>
Review:
Ontogeny of oral drug absorption processes
in children (Article)</title>
      <link>http://repub.eur.nl/res/pub/32949/</link>
      <pubDate>2012-06-12T00:00:00Z</pubDate>
      <description>A large proportion of prescribed drugs to children are administered orally. Age-related change in factors affecting oral absorption can have consequences for drug dosing. Areas covered: For each process affecting oral drug absorption, a systematic search has been performed using Medline to identify relevant articles (from inception till February 2012) in humans. This review presents the findings on age-related changes of the following processes affecting oral drug absorption: gastric pH, gastrointestinal motility, bile salts, pancreatic function, intestinal pH, intestinal drug-metabolizing enzymes and transporter proteins. Expert opinion: Clinicians should bear in mind the ontogeny of oral drug absorption processes when prescribing oral drugs to children. The authors’ review shows large information gaps on almost all drug absorption processes. It is important that more knowledge is acquired on intestinal transit time, intestinal pH and the ontogeny of intestinal drug-metabolizing enzymes and drug transporter proteins. Furthermore, the ultimate goal in this field should be to predict more precisely the oral disposition of drugs in children across the entire pediatric age range.</description>
    </item> <item>
      <title>Threonine metabolism in the intestine of mice: Loss of mucin 2 induces the threonine catabolic pathway (Article)</title>
      <link>http://repub.eur.nl/res/pub/24731/</link>
      <pubDate>2009-07-01T00:00:00Z</pubDate>
      <description>Objectives: Previous studies have shown that the intestine uses a major part of the dietary threonine intake for the synthesis of the structural component of the protective intestinal mucus layer, the secretory mucin Muc2. In this context, the high intestinal demand for dietary threonine probably results from its incorporation into secretory mucins rich in threonine residues. Therefore, we compared threonine utilization in the colon of Muc2 knockout (Muc2-/-) and wild-type (Muc2+/+) mice to investigate the intestinal dietary threonine metabolism in the absence of Muc2, which results in inflammation of the colon. Materials and Methods: Concentrations and isotopic enrichment of threonine were measured by gas chromatographyisotope ratio mass spectrometry in the serum, colon, and colonic content of mice given a bolus [U-13C]threonine enterally. Results: We retrieved 37.8% and 40.9% of dietary threonine in Muc2+/+and Muc2-/-mice, respectively, either as free or incorporated threonine. There were no major differences in the availability and concentration of free or incorporated threonine recovered in both serum and colon in both types of mice. However, the Muc2-/-mice did show overall significantly higher threonine oxidation rates compared with Muc2+/+mice. Conclusions: In the absence of Muc2, dietary threonine is mainly used for constitutive protein synthesis or becomes a substrate for metabolic oxidation. This indicates that inflammation also requires high threonine amounts. JPGN 49:99-107, 2009. </description>
    </item> <item>
      <title>Chemotherapy induced intestinal mucositis; from  bench to bed (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/10865/</link>
      <pubDate>2008-01-09T00:00:00Z</pubDate>
      <description>Part 1 focuses primarily on the pathophysiology of mucositis, in order  
to gain more insight different experimental mouse models were used.

Chapter 2 describes mucositis induced by high dose doxorubicin (DOX)- 
treatment. DOX is a frequently used cytostatic drug in childhood  
cancer, often causing severe mucositis. DOX-induced mucositis closely  
resembles the characteristics of previously studied methotrexate (MTX)- 
induced mucositis. Both drugs induce severe damage to the epithelial  
morphology, characterized by severe villus atrophy, changes in  
epithelial proliferation and loss of epithelial differentiation. We  
did not expect these similarities in morphological damage as DOX  
attacks epithelial cells much closer to the stem cell than MTX does.  
DOX was suspected to have a more severe influence on intestinal  
homeostasis in comparison to MTX. The resemblance suggests a general  
mechanism in intestinal damage and repair. The time-line however, in  
which both drugs induced their damage to the intestine was different.  
DOX-treatment leads to immediate hyper-proliferation (day 1 and 2)  
with subsequent inhibition of proliferati!
on during severe morphological damage (day 3). MTX causes  
proliferation inhibition within one day, followed by a period of hyper- 
proliferation during severe intestinal damage. Furthermore, we studied  
changes in epithelial-mesenchymal cross talk during DOX-induced  
mucositis. The expression of the intestinal morphogene and TCF4, the  
main Wnt pathway transcription factor in the intestinal epithelium  
were followed by immunohistochemistry during the different stages of  
DOX-induced mucositis. BMP4- and TCF4 expression appeared to be  
linked, shown by the fact that BMP signaling seem to suppress Wnt  
signaling and visa versa during mucositis development and  
regeneration. This suggests a balance between epithelial proliferation  
and subsequent intestinal differentiation.

Chapter 3 The objective of this study was to investigate the  
expression of the small intestinal transcription factors HNF-1a, Cdx2,  
GATA-4 in an experimental model of MTX-induced intestinal damage, and  
to correlate these alterations with histological damage, epithelial  
proliferation and differentiation. HNF-1a, Cdx2 and GATA-4 are  
critical transcription factors in epithelial differentiation, and in  
combination they act as promoting factors of the sucrase-isomaltase  
(SI) gene, an enterocyte-specific differentiation marker which is  
distinctly down regulated after MTX-treatment. Intestinal damage was  
most severe at day 3 and was associated with decreased expression of  
the transcriptional factors HNF-1a, Cdx2 and GATA-4, which correlated  
well with decreased expression of SI, and seemed inversely correlated  
with enhanced proliferation of epithelial crypt cells. During severe  
damage, the epithelium was preferentially concerned with proliferation  
rather than differentiation, most l!
ikely in order to restore the small intestinal barrier function rather  
than maintaining its absorptive function.

In Chapter 4 we show that there were no major differences found in  
intestinal pathology or protein expression during MTX-induced  
mucositis in Muc2+/+ mice in comparison to MTX-induced mucositis in  
Muc2-/- mice. Mucositis regeneration however, could not be assessed in  
the absence of Muc2 as almost all mice died spontaneously 1 day prior  
to sacrifice for evaluation. Surprisingly, however, the intestine of  
the Muc2 deficient mice evaluated just a few days after MTX-treatment  
showed already increased regeneration compared to the wild type mice.  
In addressing this question it became clear that the cytokine  
production by the mucosal immune system of Muc2 deficient mice was  
different compared to wild type littermates. Both the pro-inflammatory  
cytokine TNF-a as the anti-inflammatory cytokine Il-10 was increased  
in naÃ¯ve Muc2 deficient mice, indicating that Muc2 deficiency leads  
to induction of an inflammatory response. This suggests that MTX  
induced damage in the Muc2-/- mice may !
be tempered by triggering the immune system to release IL-10, an anti- 
inflammatory cytokine, prior to MTX-treatment.

Chapter 5 MTX is associated with severe damage of the intestinal  
epithelium. As a result, the mucosal immune cells become increasingly  
exposed to a vast amount of microbial stimuli. In this study we aimed  
at determining if and to what extent these cells are still functional  
during MTX treatment. Furthermore, we assessed whether activation of  
the mucosal immune system would play a role in the pathogenesis of  
mucositis.

The fact that the adaptive immune system contributes to mucositis was  
established by showing that lamina propria lymphocytes that were  
derived from MTX-treated mice responded by an enhanced production of  
various cytokines to ex vivo polyclonal (anti-CD3e and anti-CD28  
mAb)stimulation. Next, in vitro experiments revealed that macrophages,  
either a cell-line or cells isolated from the murine peritoneal  
cavity, were not affected by MTX in the capacity to produce TNF-Î± and  
IL-10 upon lipopolysaccharide (LPS) exposure. Moreover, in vivo  
experiments showed that peritoneal macrophages isolated from MTX  
treated mice produced more IL-10 and TNF-Î± upon LPS stimulation,  
compared to cells derived from control mice. These data indicate  
persistence of both innate and adaptive immune responses in this  
model. The clinical relevance of these findings was further  
established by the fact that LPS exposure prior to MTX treatment  
aggravated the course of mucositis. Furthermore, LPS responsive !
mice recovered more slowly compared to LPS unresponsive mice during  
MTX induced intestinal damage. Finally, we found an increase in weight  
loss and intestinal damage upon MTX treatment in IL-10 deficient mice  
in comparison to wild type (WT) controls, which suggests a protective  
role for IL-10 in mucositis.

Part 2 focuses on intestinal metabolism during mucositis and mucositis  
prophylaxis in childhood cancer patients.

In Chapter 6 we validate a new method for collecting breath samples  
that simplifies the collection of breath samples in young children in  
order to use this method in studies described in chapter 7. Stable  
isotope tracers are used in clinical studies to measure (intestinal)  
metabolism of various substrates. Nowadays, the oxidation of [13C]  
labeled substrates to 13CO2 and the measurement of the appearance of  
excess 13CO2 in expiratory air is a common method. The collection of  
respiratory CO2, occurs via trapping of CO2 in sodium hydroxide  
(trapping method) sometimes in conjunction with indirect calorimetry.  
The aim of the present study was to determine the accuracy of direct  
nasal-pharyngeal sampling method for the collection of breath samples  
in preterm infants compared with the currently used trapping method.  
Seven pre-term infants were studied while receiving full enteral  
feeding. A primed constant 3-h intragastric infusion of [13C]  
bicarbonate was given and breath samples !
were collected by means of direct nasal-pharyngeal sampling and by a  
sodium hydroxide trap simultaneously. Breath CO2 isotopic enrichments  
rose rapidly to reach a plateau by 120 min with &lt; 5% variation of  
plateau in both methods. 13CO2 breath isotopic enrichments obtained by  
the direct nasal-pharyngeal sampling method correlated highly with the  
trapping method, showing that direct nasal-pharyngeal sampling for the  
collection of breath samples is as accurate as the trapping method.

Chapter 7 The aim of this study was to evaluate systemic availability  
of dietary amino acids (leucine) during chemotherapy-induced  
mucositis. We studied eight childhood cancer patients (age 1.5 to 16  
years) on two days, i.e. the day before chemotherapy and 3-5 days  
after. Chemotherapy-induced oral mucositis and diarrhea were scored on  
a WHO toxicity scale. Stable isotope tracers were used to measure  
first-pass splanchnic leucine uptake and whole-body leucine kinetics.  
Patients showed increased mucositis and/or diarrhea toxicity scores  
after chemotherapy. Systemic availability of enterally administered  
leucine was not significantly affected by chemotherapy. Interestingly  
however was that most of the children were already catabolic prior to  
start of a new cycle of chemotherapy.

Therefore, all efforts should be directed at initiating enteral  
feeding even before start of chemotherapy in order to reduce catabolic  
state. Our data imply that this might be accomplished best by  
hydrolyzed formula.

In Chapter 8 the efficacy and feasibility of a TGF-b2-enriched feeding  
for preventing oral and gastro-intestinal mucositis in childhood  
cancer patients were studied. The study was designed as a 2-period  
crossover, randomized, double-blinded, placebo controlled trial.  
Patients who had a high risk for developing mucositis and who would  
receive two comparable cycles of chemotherapy were eligible to the  
study. During one cycle of chemotherapy TGF-b2-enriched feeding was  
administered; during the other a â€˜placeboâ€™ (not enriched) feeding  
was used. WHO toxicity scales of diarrhea, oral mucositis, fever, anal  
lesions and nausea/vomiting were scored daily. In addition, the  
incidence of occurrence of blood cultures, antibiotic therapy and  
interventions or diagnostics related to mucositis were measured. The  
feasibility of the study was good: 83% of the patients completed two  
cycles and 86% of the study feeding was consumed. Administration of  
TGF-b2 was safe, as serum TGF-b2 did not !
increase and renal and liver function were not affected. The degree of  
toxicity, scored during the whole observation period and the number of  
days with WHO 3/4 toxicity did not significantly differ between cycles  
with TGF-b2 enriched and normal feeding. These studies do not provide  
evidence that TGF- decreases the incidence or degree of mucositis  
induced by combination therapy in childhood cancer-patients.

In Part 3 all studies presented in this thesis are summarized, and new  
insights for future studies are discussed.</description>
    </item> <item>
      <title>Chemotherapy does not influence intestinal amino acid uptake in children (Article)</title>
      <link>http://repub.eur.nl/res/pub/35293/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>Chemotherapy will frequently induce intestinal damage (mucositis). Enteral nutrition is then often withheld for fear of impaired intestinal absorption as shown in animal models. There is no clinical evidence, however, that absorption is indeed compromised during chemotherapy-induced mucositis. The aim of this study was to evaluate systemic availability of dietary amino acids (leucine) during chemotherapy-induced mucositis. We studied eight childhood cancer patients (age 1.5-16 y) on 2 d, i.e. the day before chemotherapy and 3-5 d after. Chemotherapy-induced oral mucositis and diarrhea were scored on a World Health Organization toxicity scale. Stable isotope tracers were used to measure first-pass splanchnic leucine uptake and whole-body leucine kinetics. Patients showed increased mucositis and/or diarrhea toxicity scores (p &lt; 0.0001) after chemotherapy. Systemic availability of enterally administered leucine was not significantly affected by chemotherapy (before 60%, after 90%, p = 0.46). Interestingly, five patients already showed a negative leucine balance before chemotherapy. In conclusion, most children receiving chemotherapy are already catabolic before start of a new cycle of chemotherapy. Amino acid transport as measured by leucine uptake in the intestine is not affected by chemotherapy-induced mucositis. </description>
    </item> <item>
      <title>Alterations in epithelial and mesenchymal intestinal gene expression during doxorubicin-induced mucositis in mice (Article)</title>
      <link>http://repub.eur.nl/res/pub/35753/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>In the current study we aimed to gain insight into epithelial-mesenchymal cross-talk and progenitor compartment modulation during doxorubicin (DOX)-induced mucositis in mice. Intestinal segments were collected on various days after DOX treatment. DOX-induced damage at day 1-2 was characterized by increased epithelial proliferation and apoptosis and a decrease in the expression of epithelial differentiation markers. Concurrently, T-cell factor-4 (TCF4) levels increased and the epithelial differentiation enhancing factor, bone morphogenic protein-4 (BMP4), decreased. During severe damage (day 3), BMP4 levels were significantly increased, which inversely correlated with epithelial proliferation. At the same time, the expression of the epithelial differentiation markers was increasing again. At day 7, BMP4 levels were down-regulated, while the levels of the epithelial differentiation markers and TCF4 were normalized again. These data suggest that in response to DOX-induced damage, BMP4 and TCF4 are modulated in such a way that homeostasis of the progenitor compartment is partly preserved. </description>
    </item> <item>
      <title>Protection against chemotherapy induced mucositis by TGF-β2 in childhood cancer patients: Results from a randomized cross-over study (Article)</title>
      <link>http://repub.eur.nl/res/pub/37028/</link>
      <pubDate>2007-05-01T00:00:00Z</pubDate>
      <description>Background. Mucositis is one of the most frequent and severe side-effect of chemotherapy in childhood-cancer patients for which there is no prophylaxis available. The efficacy and feasibility of a TGF-β2-enriched feeding for preventing oral and gastro-intestinal-mucositis in childhood-cancer patients were studied. Procedure. The study was designed as a two-period cross-over, randomized, double-blinded, placebo, controlled trial. Patients who had a high risk for developing mucositis and who would receive two comparable cycles of chemotherapy were eligible for the study. During one cycle of chemotherapy, TGF-β2-enriched feeding was administered; during the other, a 'placebo' (not enriched) feeding was used. WHO toxicity scales of diarrhea, oral mucositis, fever, anal lesions and nausea/vomiting were scored daily. In addition, the incidence of occurrence of blood cultures, antibiotic therapy, and interventions or diagnostics related to mucositis were measured. Results. The feasibility of the study was good: 83% of the patients completed two cycles and 86% of the study-feeding was effectively consumed. Administration of TGF-β2was safe as serum TGF-β2did not increase, and renal and liver function were not affected during TGF-β2consumption compared to normal feeding. Differences in toxicity, scored during the whole observation period and the number of days with WHO 3/4 toxicity, were not significantly different between cycles with TGF-β2enriched and normal feeding. Conclusions. TGF-β2administration via feeding is well tolerated and safe. Although this study might have had limitations to show potential benefit of TGF-β2, it does not provide evidence that TGF-β2decreases the incidence or degree of mucositis induced by combination chemotherapy in childhood-cancer patients. </description>
    </item> <item>
      <title>Methotrexate-induced mucositis in mucin 2-deficient mice (Article)</title>
      <link>http://repub.eur.nl/res/pub/35637/</link>
      <pubDate>2007-01-01T00:00:00Z</pubDate>
      <description>The mucin Muc2 or Mycin2 (Muc2), which is the main structural component of the protective mucus layer, has shown to be upregulated during chemotherapy-induced mucositis. As Muc2 has shown to have protective capacities, upregulation of Muc2 may be a counter reaction of the intestine protecting against mucositis. Therefore, increasing Muc2 protein levels could be a therapeutic target in mucositis prevention or reduction. Our aim was to determine the role of Muc2 in chemotherapy-induced mucositis. Mucositis was induced in Muc2 knockout (Muc2-/-) and wild type (Muc2+/+) mice by injecting methotrexate (MTX). Animals were weighed and sacrificed on Days 2-6 after MTX treatment and jejunal segments were analyzed. Before MTX treatment, the small intestine of Muc2+/+and Muc2-/-mice were similar with respect to epithelial morphology and proliferation. Moreover, sucrase-isomaltase and trefoil factor-3 protein expression levels were comparable between Muc2+/+and Muc2-/-mice. Up to Day 3 after MTX treatment, percentages of weight-loss did not differ. Thereafter, Muc2+/+mice showed a trend towards regaining weight, whereas Muc2-/-mice continued to lose weight. Surprisingly, MTX-induced intestinal damage of Muc2-/-and Muc2+/+mice was comparable. Prior to MTX-injection, tumor necrosis factor-α and interleukin-10 mRNAs were upregulated in Muc2-/-mice, probably due to continuous exposure of the intestine to luminal antigens. Muc2 deficiency does not lead to an increase in chemotherapy-induced mucositis. A possible explanation is the mechanism by which Muc2 deficiency may trigger the immune system to release interleukin-10, an anti-inflammatory cytokine before MTX-treatment. </description>
    </item> <item>
      <title>Validation of the direct nasopharyngeal sampling method for collection of expired air in preterm neonates. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13256/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>In clinical studies, the oxidation of 13C-labeled substrates to 13CO2 and
      the measurement of the appearance of excess 13CO2 in expiratory air has
      progressed to an increasingly common method as it is noninvasive and lacks
      the radiation exposure associated with the use of 14C. The collection of
      respiratory CO2 currently used occurs via trapping of CO2 in sodium
      hydroxide (trapping method), sometimes in conjunction with indirect
      calorimetry. The aim of the present study was to determine the accuracy of
      our direct nasopharyngeal sampling method for the collection of breath
      samples in preterm infants compared with the currently used trapping
      method. We present a method that simplifies the collection of breath
      samples in preterm infants. Seven preterm infants with a gestational age
      of 26-29 wk were studied on different postnatal days (range, 8-52 d) while
      receiving full enteral feeding. A primed constant 3-h intragastric
      infusion of [13C]bicarbonate was given, and breath samples were collected
      by means of direct nasopharyngeal sampling and by a sodium hydroxide trap
      simultaneously. Breath CO2 isotopic enrichments rose rapidly to reach a
      plateau by 120 min with &lt;5% variation of plateau in both methods. 13CO2
      breath isotopic enrichments obtained by the direct nasopharyngeal sampling
      method correlated highly (r2 = 0.933; p &lt; 0.0001) with the trapping
      method. The Bland-Altman analysis showed no significant variability
      between the two methods and demonstrated that the 95% confidence interval
      is within +/- 4.68 delta per thousand. These findings validate the simple
      method of direct nasopharyngeal sampling of expired air in neonates.</description>
    </item>
  </channel>
</rss>